A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Inclusion Criteria: * Diagnosis of mild (FVIII level between \>5% and \<40%) or moderate (FVIII level between ≥1% and ≤5%) congenital Hemophilia A without FVIII inhibitors * Weight ≥3 kilograms (kg) * Need for prophylaxis based on investigator assessment * A negative test for inhibitor (i.e., \<0.6 Bethesda Units per milliliter \[BU/mL\]) within 8 weeks prior to enrollment * No documented inhibitor (i.e., \<0.6 BU/mL), FVIII half-life \<6 hours, or FVIII recovery \<66% in the last 5 years * Documentation of the details of prophylactic or episodic FVIII treatment and of number of bleeding episodes for at least the last 24 weeks prior to enrollment * Adequate hematologic, hepatic, and renal function * For women of childbearing potential: agreement to remain abstinent or use contraception (as defined in the protocol) during the treatment period and for at least 24 weeks after the final dose of study drug Exclusion Criteria: * Inherited or acquired bleeding disorder other than mild or moderate congenital hemophilia A * History of illicit drug or alcohol abuse within 48 weeks prior to screening, in the investigator's judgment * Previous (within the last 12 months) or current treatment for thromboembolic disease or signs of thromboembolic disease * Other conditions that may currently increase the risk of bleeding or thrombosis * History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection * Planned sur…